bioMérieux S.A. (FRA:EYWN)

Market Cap	14.88B
Revenue (ttm)	3.98B
Net Income (ttm)	432.20M
Shares Out	n/a
EPS (ttm)	3.64
PE Ratio	34.44
Forward PE	27.81
Dividend	0.90 (0.72%)
Ex-Dividend Date	Jun 9, 2025

Volume	40
Average Volume	24
Open	125.00
Previous Close	124.50
Day's Range	125.00 - 125.00
52-Week Range	96.25 - 126.20
Beta	n/a
RSI	57.78
Earnings Date	Sep 4, 2025

About bioMérieux

bioMérieux S.A. develops and markets in vitro diagnostic solutions for infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemase producing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO or 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VI...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1963
• Employees: 14,754
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: EYWN

Financial Performance

In 2024, bioMérieux's revenue was 3.98 billion, an increase of 8.31% compared to the previous year's 3.67 billion. Earnings were 432.20 million, an increase of 20.86%.